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Purpose: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been implicated as a
potential risk factor for epilepsy. To date, many case–control studies have investigated the association
between MTHFR C677T polymorphism and epilepsy susceptibility. However, those ﬁndings were
inconsistent. The objective of this study is to evaluate the precise association between MTHFR C677T
polymorphism and epilepsy.
Methods: An electronic search of PubMed, EMBASE for papers on the MTHFR C677T polymorphism and
epilepsy susceptibility was performed. Odds ratios (ORs) with 95% conﬁdence intervals (CIs) were
calculated to assess the association.
Results: Ten case–control studies containing 1713 cases and 1867 controls regarding MTHFR C677T
polymorphism were selected. A signiﬁcant association between the MTHFR C677T polymorphism and
epilepsy susceptibility was revealed in this meta-analysis (for T vs. C: OR = 1.19, 95% CI = 1.08–1.32; for
TT + CT vs. CC: OR = 1.20, 95% CI = 1.05–1.38; for TT vs. CC: OR = 1.48, 95% CI = 1.20–1.83; for TT vs.
CT + CC: OR = 1.35, 95% CI = 1.12–1.64). In subgroup analysis by ethnicity, the results also indicated the
association between the MTHFR C677T polymorphism and epilepsy susceptibility within the Asian
populations (for T vs. C: OR = 1.55, 95% CI = 1.15-2.07; for TT + CT vs. CC: OR = 1.67, 95% CI = 1.08-2.59;
for TT vs. CC: OR = 2.33, 95% CI = 1.30-4.20; for TT vs. CT + CC: OR = 1.89, 95% CI = 1.12-3.18).
Conclusion: The results indicated that MTHFR C677T polymorphism was associated with an increased
risk of epilepsy. However, further studies in various regions are needed to conﬁrm the ﬁndings from this
meta-analysis.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of the most common neurologic conditions and a
cause of substantial morbidity and mortality. Around 50 million
people around the world are likely to suffer from epilepsy1 and its
etiologies include genetic, structural, and metabolic factors.2
Genetic factors may play a role in most cases, as either the
underlying cause is primarily genetic, or there are genes that
modulate the susceptibility to this disease.3 Studies of the* Corresponding author. Tel.: +86 551 65143334; fax: +86 551 65143334.
E-mail address: yhsun_ahmu_edu@yeah.net (Y.-H. Sun).
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1059-1311/$ – see front matter  2014 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2014.01.018neurophysiologic and neurodevelopmental effects of mutations
in related genes can elucidate the underlying epileptogenic
mechanisms and obtained such information may help to promote
the development of new treatments targeted and ways of
preventing epileptogenesis.4
Genome-wide scans and other previous studies which aimed at
ﬁnding susceptibility genes for epilepsy have implicated mostly
ion channel and ligand receptor genes.5,6 Methylenetetrahydro-
folate reductase (MTHFR) C677T polymorphism as another
candidate risk gene for epilepsy has been investigated for many
years. MTHFR plays an important role in folate metabolism, which
catalyzes the reduction of 5,10-methylenetetrahydrofolate to
produce 5-methyltetrahydrofolate. The product is the dominant
form of circulating folate, and provides a methyl group for thevier Ltd. All rights reserved.
Y.-L. Wu et al. / Seizure 23 (2014) 411–416412remethylation of homocysteine (Hcy) back to methionine. A
common MTHFR polymorphism, 677C-T transition results in
decreased enzyme activity and elevated plasma Hcy levels.7,8
The latter is known to cause vascular endothelial damage,9
enhanced apoptosis,10 DNA hypomethylation11 and may be
associated with a direct effect on neurodevelopment.12 MTHFR
C677T polymorphism has been associated with vascular disease,13
congenital heart defects,14 and some neurological diseases
including Alzheimer’s disease,15 Parkinson’s disease16 and schizo-
phrenia.17 Previous studies also showed an association between
the MTHFR C677T polymorphism and epilepsy.5,18,19 Several lines
of evidence suggest a role for the MTHFR C677T polymorphism as a
predisposing factor for epilepsy. Lipton et al. founded that Hcy may
have excitotoxicity to neurons as an agonist at the glutamate site of
the N-methyl-D-aspartate (NMDA) receptors.20 In an animal
model, it was demonstrated that the NMDA receptor antagonist
was protective against seizures induced by Hcy.21 Furthermore,
other studies have suggested that Hcy lowered seizure thresholds
and has been exploited as a pro-convulsant in models of
experimental epilepsy.22,23 In addition, the 677TT genotype has
been identiﬁed as a risk factor for migraines with aura,24 a
condition that may share pathophysiological mechanisms with
epilepsy. Hence, it is possible that the MTHFR C677T variant may
be a predisposing factor for epilepsy.18
Many previous studies have been performed to investigate the
association between MTHFR C677T gene polymorphism and
epilepsy susceptibility. However, the ﬁndings were inconsistent,
which may be due to the limitation of individual study sample
sizes. Therefore, we performed this meta-analysis including all
available case–control studies to clarify the effect of MTHFR C677T
polymorphism on the risk of epilepsy.
2. Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) statement was consulted to report this
review.25
2.1. Search strategy and selection criteria
Potentially relevant articles were selected by searching
PubMed, EMBASE databases using the search terms ‘‘MTHFR’’,
‘‘methylenetetrahydrofolate reductase’’ ‘‘C677T’’, ‘‘MTHFR C677T’’,
and ‘‘epilepsy’’, ‘‘epileptic’’. Related reference articles were also
searched to identify other relevant publications. All researches
were limited to English literatures published up to October 2013.
2.2. Inclusion and exclusion criteria
The eligible publications must meet the following inclusion
criteria: (1) examining the association between MTHFR C677T
polymorphism and epilepsy; (2) the study was using a case–
control study design; (3) providing enough data on genotype
frequencies of the MTHFR C677T polymorphism for calculating an
odd ratio (OR) with 95% conﬁdence interval (95% CI). The exclusion
criteria included: (1) a review or case report; (2) a duplicated
study. If studies contained overlapping cases and/or controls, the
largest study was preferred.
2.3. Data extraction
According to the inclusion and exclusion criteria, data were
extracted independently from each study by two authors (Wu and
Yang) and the consensus was achieved for all data. The following
information was extracted from each study included: the ﬁrst
author’s name, year of publication, ethnicity of study population,source of controls, number of cases and controls for each
genotype.
2.4. Statistical analysis
The strength of association between MTHFR C677T polymor-
phism and epilepsy susceptibility was assessed by ORs with 95%
CIs. The pooled ORs were performed for the allele model (T vs. C),
the dominant model (TT + CT vs. CC), the homozygote model (TT vs.
CC) and the recessive model (TT vs. CT + CC). Moreover, a Chi-
square test was used to determine whether the observed
frequencies of the genotypes in the controls conformed to
Hardy–Weinberg Equilibrium (HWE) expectations. Heterogeneity
among the studies was quantized by the I2 statistics. I2 > 50%
indicated an obvious of the between-study heterogeneity,26 the
pooled OR was calculated by the random effects model;27
otherwise, the ﬁxed effects model was used.28 Additionally,
sensitivity analyses were performed to assess the stability of the
meta-analysis results by sequential removal of each study. Finally,
the Begg’s tests and Egger’s tests were used to analyze the
publication bias.29 All statistical analyses were conducted using
Stata 9.0 (StataCrop, College Station, TX). A P value less than 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of eligible studies
A detailed process for selecting eligible studies was shown in
Fig. 1. Based on the search criteria, a total of 81 potentially relevant
publications were identiﬁed, and three of them were selected from
the reference lists of the identiﬁed articles. After careful selection,
10 eligible studies5,18,19,30–36 were ﬁnally included in this meta-
analysis. All control samples from included studies were in HWE.
Detailed characteristics of included studies were summarized in
Table 1.
3.2. Quantitative synthesis
The heterogeneity was not signiﬁcant in all the genetic
models (I2 < 50%) and the ﬁxed effects model was therefore
used in this meta-analysis. The association was detected
between the MTHFR C677T polymorphism and epilepsy
susceptibility in all the genetic models (Table 2, for T vs. C:
OR = 1.19, 95% CI = 1.08–1.32; for TT + CT vs. CC: OR = 1.20, 95%
CI = 1.05–1.38; for TT vs. CC: OR = 1.48, 95% CI = 1.20–1.83; for
TT vs. CT + CC: OR = 1.35, 95% CI = 1.12–1.64, forest plots were
shown in Fig. 2). The sensitivity analyses did not alter the
results. Consequently, it demonstrated the results of this study
were robust. In subgroup analysis by ethnicity, results indicated
that the MTHFR C677T polymorphism was associated with an
increased risk of epilepsy in Asian populations (for T vs. C:
OR = 1.55, 95% CI = 1.15-2.07; for TT + CT vs. CC: OR = 1.67, 95%
CI = 1.08-2.59; for TT vs. CC: OR = 2.33, 95% CI = 1.30-4.20; for TT
vs. CT + CC: OR = 1.89, 95% CI = 1.12-3.18).However, we were
unable to detect any association between the MTHFR C677T
polymorphism and epilepsy susceptibility in white populations.
3.3. Publication bias
The funnel plot was basically symmetric, indicating that no
obvious evidence of publication bias in this meta-analysis
(Supplemental Fig. S1). Furthermore, neither the Begg’s test nor
the Egger’s test detected any obvious evidence of publication bias
in all the genetic models (Table 2).
Table 1
Characteristics of 10 case–control studies included in this meta-analysis.
First author Year Country Ethnicity Deﬁnition of epilepsy Case Control PHWE SOC
CC CT TT CC CT TT
Yoo 1999 Korea Asian Clinical records 25 54 24 37 53 13 0.37 PB
Vilaseca 2000 Spain White ILAE 19 30 10 7 17 4 0.23 HB
Ono 2000 Japan Asian ILAE 24 29 19 43 37 17 0.08 NA
Caccamo 2004 Italy White ILAE 26 50 19 33 47 18 0.86 PB
Kini 2007 UK White Clinical records 50 75 16 85 115 26 0.17 PB
Dean 2008 UK White ILAE 64 80 26 146 128 29 0.90 PB
Gorgone 2009 Italy White ILAE 14 30 16 18 26 14 0.45 PB
Belcastro 2010 Italy White Clinical records 68 119 72 60 110 61 0.47 PB
Sniezawska 2011 Poland White ILAE 36 22 7 24 29 2 0.06 NA
Scher 2011 USA Mixed ICD-9-CM 350 262 77 366 249 53 0.25 PB
Abbreviations: ILAE, International League Against Epilepsy; ICD-9-CM, The International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation; PHWE, P-value for
Hardy–Weinberg Equilibrium in control group; SOC, source of controls; PB, population-based; HB, hospital-based; Mixed, including white, black and other population; NA,
not available.
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Fig. 1. PRISMA ﬂow diagram for inclusion of the studies examining the association between MTHFR C677T polymorphism and epilepsy susceptibility. PRISMA, Preferred
Reporting Items for Systematic Review and Meta-Analyses.
Table 2
Meta-analysis of the MTHFR gene polymorphism on epilepsy risk.
Studies Comparison model Test of association M* I2(%) P (publication bias test)
OR(95%CI) POR Begg’s test Egger’s test
All studies T vs. C 1.19(1.08–1.32) <0.001 F 0.0 0.86 0.93
TT + CT vs. CC 1.20(1.05–1.38) 0.009 F 6.3 0.47 0.89
TT vs. CC 1.48(1.20–1.83) <0.001 F 0.0 0.72 0.62
TT vs. CT + CC 1.35(1.12–1.64) 0.002 F 0.0 0.28 0.86
Caucasian T vs. C 1.13(0.99–1.29) 0.080 F 0.0 – –
TT + CT vs. CC 1.15(0.94–1.40) 0.175 F 15.6 – –
TT vs. CC 1.31(0.98–1.74) 0.065 F 0.0 – –
TT vs. CT + CC 1.21(0.95–1.55) 0.130 F 0.0 – –
Asian T vs. C 1.55(1.15–2.07) 0.003 F 0.0 – –
TT + CT vs. CC 1.67(1.08–2.59) 0.021 F 0.0 – –
TT vs. CC 2.33(1.30–4.20) 0.005 F 0.0 – –
TT vs. CT + CC 1.89(1.12–3.18) 0.017 F 0.0 – –
M*, model of meta-analysis; F, ﬁxed effect model.
Y.-L. Wu et al. / Seizure 23 (2014) 411–416 413
Overall  (I-squared = 0.0% , p = 0.6 03)
Dean (2008)
Yoo (1999)
Sniezaws ka (2011)
Scher (2011)
Vilaseca (2000)
ID
Kini (2007)
Belcastro (2010)
Gorg one (2009)
Ono (2 000)
Cacca mo (2004)
Study
1.48 (1.20, 1.83)
2.05 (1.12, 3.75)
2.73 (1.17, 6.36)
2.33 (0.45, 12. 20)
1.52 (1.04, 2.22)
0.92 (0.22, 3.92)
OR (95% CI)
1.05 (0.51, 2.14)
1.04 (0.64, 1.69)
1.47 (0.54, 4.00)
2.00 (0.88, 4.56)
1.34 (0.59, 3.06)
100.0 0
9.95
4.66
1.48
31.15
2.70
Weight
10.43
22.58
4.49
5.63
6.93
%
1.082  12.2
TT vs. CC
Overall  (I-squared = 0.0% , p = 0.7 14)
Gorg one (2009)
ID
Kini (2007)
Cacca mo (2004)
Vilaseca (2000)
Ono (2 000)
Yoo (1999)
Scher (2011)
Belcastro (2010)
Dean (2008)
Sniezaws ka (2011)
Study
1.35 (1.12, 1.64)
1.14 (0.50, 2.62)
OR (95% CI)
0.98 (0.51, 1.91)
1.11 (0.54, 2.28)
1.22 (0.35, 4.31)
1.69 (0.80, 3.54)
2.10 (1.00, 4.41)
1.46 (1.01, 2.11)
1.07 (0.72, 1.60)
1.71 (0.97, 3.01)
3.20 (0.64, 16. 08)
100.0 0
5.75
Weight
9.76
7.81
2.48
5.88
5.50
26.35
25.66
9.73
1.07
%
1.0622  16.1
TT vs. C T+CC
Overall   (I-squ ared = 0.0%, p = 0.475)
Stud y
Ono (2000 )
Belcastro (2010 )
Sche r (2011)
Yoo (19 99)
Vilaseca (2000)
Cacc amo (2004 )
ID
Dean (2008)
Kini  (2007)
Snie zawska (20 11)
Gorgo ne (20 09)
1.19  (1.08,  1.32)
1.51  (0.97,  2.34)
1.02  (0.80,  1.31)
1.19  (1.01,  1.41)
1.58  (1.07,  2.33)
0.91  (0.48,  1.73)
1.17  (0.79,  1.76)
OR  (95%  CI)
1.43  (1.09,  1.89)
1.04  (0.77,  1.42)
0.89  (0.51,  1.56)
1.23  (0.74,  2.05)
100.00
%
4.48
16.73
34.86
5.53
2.71
6.08
Weight
11.33
11.03
3.58
3.68
1.428 2.34
T vs. C
Overall   (I-squ ared = 6.3%, p = 0.383)
Ono (2000 )
Gorgo ne (20 09)
Yoo (19 99)
Kini  (2007)
Belcastro (2010 )
Vilaseca (2000)
ID
Stud y
Dean (2008)
Sche r (2011)
Cacc amo (2004 )
Snie zawska (20 11)
1.20  (1.05,  1.38)
1.59  (0.85,  3.00)
1.48  (0.65,  3.35)
1.75  (0.96,  3.20)
1.10  (0.71,  1.70)
0.99  (0.66,  1.48)
0.70  (0.25,  1.94)
OR  (95%  CI)
1.54  (1.05,  2.26)
1.17  (0.95,  1.45)
1.35  (0.73,  2.49)
0.62  (0.30,  1.29)
100.00
4.14
2.56
4.33
10.38
12.82
2.48
Weight
%
11.47
42.07
4.73
5.02
1.254 3.93
TT+C T vs. CC
Fig. 2. Forest plots for the association between MTHFR C677T polymorphism and epilepsy for four genotype models.
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Many case–control studies have been performed to investigate
the association between MTHFR C677T polymorphism and epilepsy,
but the available evidence is still weak due to inconsistent ﬁndings
among those studies. The contradictory results obtained from those
studies may partly be due to a small sample size in individual studies
or differences in various ethnic groups. Meta-analysis has been
recognized as a useful statistical method that combines ﬁndings
from independent studies to precisely evaluate the effect of selected
genetic polymorphism on the risk of disease.37 To the best of our
knowledge, no meta-analysis has been conducted to assess the
association between MTHFR C677T polymorphism and epilepsy.
Therefore, there is a need to perform a meta-analysis using
published data to clarify inconsistent ﬁndings.
Based on 10 case–control studies, this meta-analysis revealed
that MTHFR C677T polymorphism was associated with an
increased risk of epilepsy in all genetic models. The sensitivity
analyses did not substantively alter the results, indicating that
results of this study were robust and reliable. T variant of the
MTHFR C677T gene results in reduced MTHFR enzyme activity and
elevated plasma Hcy levels. With a signiﬁcant reduction in MTHFR
activity, Hcy cannot be remethylated to methionine, hence
accumulates within the nervous system.38 Hcy is directly toxic
to neurons and endothelial cells and can induce DNA strand
breakage, oxidative stress, and apoptosis.41 Study have shown thatHcy substantially increased the vulnerability of hippocampal
neurons to excitotoxic and oxidative injury in cell cultures and in
vivo, suggesting Hcy may contribute to the pathogenesis of
neurodegenerative disorders.42 Patients with severe hyperhomo-
cysteinemia exhibit a wide range of clinical manifestations
including neurological abnormalities such as mental retardation
and cerebral atrophy.43 Consequently, it is biologically plausible
that the elevated plasma Hcy may be an intermediary factor
involved in the mechanism of MTHFR C677T polymorphism that
results in epilepsy. The other common functional variants in this
enzyme, MTHFR A1298C, as another candidate risk gene for
epilepsy have also been investigated in previous studies,5,18,32 but
ﬁndings were inconsistent. An earlier study with 95 cases and 98
controls conducted by Caccamo et al. suggested that the frequency
of C1298 polymorphic allele was signiﬁcantly higher in patients
with epilepsy as compared to controls (30.5% vs. 19.4%, P < 0.05).32
Nevertheless, no signiﬁcant association between MTHFR A1298C
polymorphism and epilepsy was detected in the subsequent
studies with relatively large samples.5,18 However, MTHFR A1298C
polymorphism is believed to have a marginal or no effect on
plasma Hcy concentration.39,40 Consequently, this less interference
with Hcy levels caused by MTHFR A1298C polymorphism might
account for the lack of signiﬁcant association. It would be useful to
study the MTHFR A1298C polymorphism and look at polymorph-
isms in other genes involved in the folate metabolic pathway, but
that would have increased the sample size further.
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that the MTHFR C677T polymorphism was associated with
signiﬁcantly increased epilepsy susceptibility in Asian populations
in all genetic models. However, this association cannot be detected
in white populations in any genetic model. Hence, some potential
factors may contribute to the results that the same gene
polymorphism affects different ethnic populations. Firstly, the
differences in genetic backgrounds may play a role. Secondly,
epilepsy is a multi-factorial chronic disease with socioeconomic
status, access to health care and environmental exposure such as
neurocysticercosis involved in its pathophysiology.44 It is possible
that individual susceptibility in different ethnic populations may
be modiﬁed by those factors. In addition, the signiﬁcant association
between MTHFR C677T polymorphism and epilepsy within the
Asian populations may be false positive due to a small sample size.
Thus, further studies with larger samples are needed to conﬁrm the
association found within this ethnic group.
Several potential limitations of this meta-analysis should be
acknowledged. (1) The overall outcomes were based on individual
unadjusted ORs due to unavailable data, whereas a more precise
estimation should be adjusted by potentially inﬂuential factors
including age, gender, and environmental factors. (2) The wrong
diagnosis of epilepsy occurring worldwide may contribute to the
ethnic group variations in subgroup analysis. For instance, among
patients diagnosed with epilepsy, 20–30% are found to have been
misdiagnosed.45,46 Consequently, the observed effect of MTHFR
C677T polymorphism may be alleviated by the incorrect diagnosis
of epilepsy. (3) Although neither the funnel plots nor the Begg’s test
or Egger’s test detected any obvious evidence of publication bias,
selection bias may have occurred attributed to the fact that only
English and published articles were included in this meta-analysis.
In conclusion, the present meta-analysis revealed that MTHFR
C677T polymorphism was a risk factor for epilepsy in overall
populations and Asian populations. However, the association
between MTHFR C677T polymorphism and epilepsy could not be
detected within white populations. Future studies with larger
sample sizes are warranted to further conﬁrm these ﬁndings.
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